Veterinary Epidemiology Unit, Department of Reproduction, Obstetrics and Herd Health, Faculty of Veterinary Medicine, Ghent University, 9820 Merelbeke, Belgium.
Department of Pathology, Bacteriology and Avian Diseases, Faculty of Veterinary Medicine, Ghent University, 9820 Merelbeke, Belgium.
J Antimicrob Chemother. 2017 Jul 1;72(7):1991-2001. doi: 10.1093/jac/dkx104.
Factors potentially contributing to fluoroquinolone resistance selection in commensal Escherichia coli strains in poultry were studied through a series of in vivo experiments. The effect of the initial prevalence of enrofloxacin resistance in the E. coli gut microbiota, effect of the bacterial fitness of the enrofloxacin-resistant strain and effect of treatment with enrofloxacin (effect of dose and effect of route of administration) were assessed.
Four in vivo studies with broiler chickens were performed. Right after hatching, the chicks were inoculated with either a bacteriologically fit or a bacteriologically non-fit fluoroquinolone-resistant strain as either a minority or the majority of the total E. coli population. Six days later, the chicks were treated for three consecutive days either orally or parenterally and using three different doses (under-, correct- and over-dose) of enrofloxacin. The faecal shedding of E. coli strains was quantified by plating on agar plates either supplemented or not supplemented with enrofloxacin. Linear mixed models were used to assess the effect of the aforementioned variables on the selection of enrofloxacin resistance.
The factors that significantly contributed were treatment ( P < 0.001), bacterial fitness of the resistant donor strain ( P < 0.001), administration route ( P = 0.052) and interactions between bacterial fitness and administration route ( P < 0.001).
In the currently used models, fluoroquinolone resistance selection was influenced by treatment, bacterial fitness of the inoculation strain and administration route. The use of oral treatment seems to select more for fluoroquinolone resistance, particularly in the model where a non-fit strain was used for inoculation.
通过一系列体内实验研究了可能导致禽源共生大肠杆菌菌株氟喹诺酮耐药选择的因素。评估了肠道微生物群中恩诺沙星初始耐药率、恩诺沙星耐药株细菌适应性和恩诺沙星治疗(剂量效应和给药途径效应)的影响。
对 4 项肉鸡体内研究进行了评估。在孵化后,小鸡被接种了具有细菌适应性或不具有细菌适应性的氟喹诺酮耐药株,作为总大肠杆菌种群的少数或多数。6 天后,小鸡连续 3 天接受口服或胃肠外治疗,并使用 3 种不同剂量(低剂量、正确剂量和高剂量)的恩诺沙星。通过在含有或不含有恩诺沙星的琼脂平板上进行平板计数来量化大肠杆菌菌株的粪便脱落。使用线性混合模型评估上述变量对恩诺沙星耐药性选择的影响。
显著相关的因素是治疗(P < 0.001)、耐药供体菌株的细菌适应性(P < 0.001)、给药途径(P = 0.052)和细菌适应性与给药途径之间的相互作用(P < 0.001)。
在目前使用的模型中,氟喹诺酮耐药性选择受治疗、接种菌株的细菌适应性和给药途径的影响。口服治疗似乎更能选择氟喹诺酮耐药性,特别是在使用不适应菌株进行接种的模型中。